NERV Stock Summary and Trading Ideas (Minerva Neurosciences | NASDAQ:NERV)

Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.

Minerva Neurosciences trades on the NASDAQ stock market under the symbol NERV.

As of January 22, 2026, NERV stock price declined to $3.90 with 152,312 million shares trading.

NERV has a beta of 1.78, meaning it tends to be more sensitive to market movements. NERV has a correlation of 0.11 to the broad based SPY ETF.

NERV has a market cap of $168.77 million. This is considered a Micro Cap stock.

In the last 3 years, NERV traded as high as $13.49 and as low as $1.15.

The top ETF exchange traded funds that NERV belongs to (by Net Assets): VTI, VXF.

NERV has outperformed the market in the last year with a return of +78.5%, while the SPY ETF gained +15.5%. However, in the most recent history, NERV shares have underperformed the stock market with its stock returning -39.2% in the last 3 month period and -17.2% for the last 2 week period, while SPY has returned +2.9% and -0.1%, respectively.

NERV support price is $3.96 and resistance is $4.42 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NERV shares will trade within this expected range on the day.